NCT04141020
Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 18 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Enrollment closed, study ongoing
- Final enrollment: 26 participants (planned 80)
- Site details revised
- Minor Site contact updatedv21
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Nov 1, 2021 to Oct 27, 2021
- Site details revised
- Notable Start date: Sep 1, 2021 to Nov 1, 2021
- Primary and study completion dates: Sep 1, 2026 to Nov 1, 2026
- Notable Start date: Aug 1, 2021 to Sep 1, 2021
- Primary and study completion dates: Aug 1, 2026 to Sep 1, 2026
Show 12 earlier versionsHide 12 earlier versions
- Notable Start date: Jun 1, 2021 to Aug 1, 2021
- Primary and study completion dates: Jun 1, 2026 to Aug 1, 2026
- Notable Start date: Apr 1, 2021 to Jun 1, 2021
- Primary and study completion dates: Apr 1, 2026 to Jun 1, 2026
- Notable Start date: Jan 1, 2021 to Apr 1, 2021
- Primary and study completion dates: Jan 1, 2026 to Apr 1, 2026
- Notable Start date: Dec 1, 2020 to Jan 1, 2021
- Primary and study completion dates: Dec 1, 2025 to Jan 1, 2026
- Notable Start date: Oct 1, 2020 to Dec 1, 2020
- Primary and study completion dates: Oct 1, 2025 to Dec 1, 2025
- Notable Start date: Sep 1, 2020 to Oct 1, 2020
- Primary and study completion dates: Sep 1, 2025 to Oct 1, 2025
- Notable Start date: Aug 1, 2020 to Sep 1, 2020
- Primary and study completion dates: Aug 1, 2025 to Sep 1, 2025
- Notable Start date: Jun 1, 2020 to Aug 1, 2020
- Primary and study completion dates: Jun 1, 2025 to Aug 1, 2025
- Notable Start date: May 1, 2020 to Jun 1, 2020
- Primary and study completion dates: May 1, 2025 to Jun 1, 2025
- Notable Start date: Apr 1, 2020 to May 1, 2020
- Primary and study completion dates: Apr 1, 2025 to May 1, 2025
- Collaborators expanded, about 8 words
- Study arms: 4 to 2
- Notable Start date: Mar 1, 2020 to Apr 1, 2020
- Primary and study completion dates: Mar 1, 2025 to Apr 1, 2025
- Notable Start date: Jan 1, 2020 to Mar 1, 2020
- Primary and study completion dates: Jan 1, 2025 to Mar 1, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in gene expression from control arteries.
Timeframe: Day 18
Change in gene expression between blood samples.
Timeframe: Day 18
Change in gene expression.
Timeframe: Day 18
Arms and interventions
Microsurgical Clipping Treated with SirolimusExperimental
Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.
Endovascular Treatment Treated with SirolimusExperimental
Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.
Procedures: Microsurgical clipping, Endovascular treatment
Drugs: Sirolimus
Sites
1 site in 1 country
- University of MiamiMiami, Florida, United States